TWi Biotechnology Receives Canada Health Approval for AC-1101 ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
TAIPEI, Taiwan, May 7, 2020 /PRNewswire-AsiaNet/ -- TWi Biotechnology (TWiB) announced that they have received Clinical Trial Application (CTA) approval from the Health Canada to conduct a Phase 1 clinical trial with AC-1101 gel. AC-1101 is a topical JAK inhibitor for the potential treatment of pat...
Authors: LATEST ASIANET NEWS RELEASES